Haruhiko Kamada Selected Research

Type I Tumor Necrosis Factor Receptors

10/2020	Structural optimization of a TNFR1-selective antagonistic TNFα mutant to create new-modality TNF-regulating biologics.
1/2017	A trimeric structural fusion of an antagonistic tumor necrosis factor-α mutant enhances molecular stability and enables facile modification.
2/2015	Aminopeptidase P3, a new member of the TNF-TNFR2 signaling complex, induces phosphorylation of JNK1 and JNK2.
1/2012	Novel TNF-α receptor 1 antagonist treatment attenuates arterial inflammation and intimal hyperplasia in mice.
1/2011	Therapeutic effect of PEGylated TNFR1-selective antagonistic mutant TNF in experimental autoimmune encephalomyelitis mice.
12/2009	The treatment of established murine collagen-induced arthritis with a TNFR1-selective antagonistic mutant TNF.
10/2009	Novel protein engineering strategy for creating highly receptor-selective mutant TNFs.
8/2009	Fast binding kinetics and conserved 3D structure underlie the antagonistic activity of mutant TNF: useful information for designing artificial proteo-antagonists.
11/2008	The therapeutic effect of TNFR1-selective antagonistic mutant TNF-alpha in murine hepatitis models.
1/2008	Creation and X-ray structure analysis of the tumor necrosis factor receptor-1-selective mutant of a tumor necrosis factor-alpha antagonist.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Haruhiko Kamada Research Topics

Disease

25	Neoplasms (Cancer) 01/2020 - 06/2003
7	Breast Neoplasms (Breast Cancer) 01/2015 - 09/2007
6	Inflammation (Inflammations) 01/2016 - 03/2004
5	Infections 10/2021 - 07/2009
4	Autoimmune Diseases (Autoimmune Disease) 10/2020 - 08/2009
4	Rheumatoid Arthritis 10/2020 - 01/2008
3	COVID-19 11/2021 - 10/2021
3	Neoplasm Metastasis (Metastasis) 07/2015 - 09/2007
3	Necrosis 08/2009 - 03/2004
2	Acute Lung Injury 11/2021 - 10/2021
2	Lung Injury 11/2021 - 05/2004
2	Hypersensitivity (Allergy) 01/2016 - 06/2015
2	Lung Neoplasms (Lung Cancer) 07/2015 - 02/2011
2	Atopic Dermatitis (Atopic Eczema) 06/2015 - 02/2012
2	Triple Negative Breast Neoplasms 01/2015 - 09/2014
2	Virus Diseases (Viral Diseases) 01/2010 - 12/2009
2	Hepatitis 11/2008 - 01/2008
2	Asthma (Bronchial Asthma) 05/2004 - 03/2004
2	Acute Kidney Injury (Acute Renal Failure) 03/2004 - 04/2003
1	Diabetic Nephropathies (Diabetic Nephropathy) 01/2022
1	Chronic Renal Insufficiency 01/2022
1	Cardiovascular Diseases (Cardiovascular Disease) 11/2021
1	Pneumonia (Pneumonitis) 10/2021
1	Reinfection 10/2021
1	Body Weight (Weight, Body) 10/2021
1	Contact Dermatitis (Eczema, Contact) 01/2021
1	Experimental Arthritis 10/2020
1	Arthritis (Polyarthritis) 10/2020
1	Graft vs Host Disease (Graft-Versus-Host Disease) 01/2020
1	Hypoxia (Hypoxemia) 01/2016
1	Obesity 09/2015
1	Anaphylaxis (Anaphylactic Shock) 06/2015
1	Colonic Neoplasms (Colon Cancer) 07/2014
1	Prostatic Neoplasms (Prostate Cancer) 07/2014
1	Lymphatic Metastasis 12/2013
1	Amyloid Plaque 02/2013
1	Alzheimer Disease (Alzheimer's Disease) 02/2013
1	Immune System Diseases (Immune Disorders) 10/2012
1	Malignant Mesothelioma 04/2012

Drug/Important Bio-Agent (IBA)

14	Proteins (Proteins, Gene)FDA Link 01/2022 - 02/2009
11	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 10/2020 - 03/2004
10	Type I Tumor Necrosis Factor ReceptorsIBA 10/2020 - 01/2008
9	CytokinesIBA 10/2021 - 03/2004
6	Type II Tumor Necrosis Factor ReceptorsIBA 10/2020 - 03/2009
6	antineoplaston A10 (A 10)IBA 01/2015 - 01/2011
5	Biological ProductsIBA 01/2016 - 02/2004
4	Silicon Dioxide (Silica)FDA LinkGeneric 06/2015 - 05/2011
4	EphA1 Receptor (Eph Receptor)IBA 01/2015 - 01/2011
3	Biomarkers (Surrogate Marker)IBA 01/2022 - 01/2011
3	VaccinesIBA 10/2021 - 01/2010
3	ChemokinesIBA 10/2021 - 01/2012
3	AntibodiesIBA 01/2020 - 01/2010
3	Pharmaceutical PreparationsIBA 01/2016 - 07/2014
3	ProteomeIBA 07/2015 - 02/2011
3	Monoclonal AntibodiesIBA 09/2014 - 01/2010
3	Protein CIBA 09/2007 - 02/2004
2	Immunoglobulin G (IgG)IBA 01/2021 - 06/2015
2	Immunoglobulin E (IgE)IBA 06/2015 - 03/2004
2	AntigensIBA 01/2015 - 10/2012
2	EphrinsIBA 01/2015 - 09/2014
2	Messenger RNA (mRNA)IBA 07/2014 - 12/2013
2	Tumor Necrosis Factor Receptors (Tumor Necrosis Factor Receptor)IBA 01/2012 - 12/2009
2	Therapeutic UsesIBA 01/2011 - 11/2008
2	Peptides (Polypeptides)IBA 07/2009 - 11/2007
2	AnticoagulantsIBA 09/2007 - 02/2004
2	Protein C InhibitorIBA 09/2007 - 02/2004
2	Urokinase-Type Plasminogen Activator (Urokinase)FDA Link 09/2007 - 02/2004
2	poly(vinylpyrrolidone-co-dimethyl maleic anhydride)IBA 05/2006 - 04/2003
2	Drug CarriersIBA 05/2006 - 04/2004
2	Antineoplastic Agents (Antineoplastics)IBA 12/2004 - 03/2004
2	OvalbuminIBA 05/2004 - 03/2004
1	Blood Glucose (Blood Sugar)IBA 01/2022
1	EnzymesIBA 11/2021
1	AcidsIBA 11/2021
1	CarboxypeptidasesIBA 11/2021
1	Angiotensin IIIBA 11/2021
1	Angiotensin-Converting Enzyme 2IBA 11/2021
1	Viral RNAIBA 10/2021
1	Viral AntigensIBA 10/2021
1	Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA 10/2021
1	GlypicansIBA 01/2020
1	Chimeric Antigen ReceptorsIBA 01/2020
1	Neutralizing AntibodiesIBA 01/2018
1	Capsid Proteins (Capsid Protein)IBA 01/2018
1	furospinosulin-1IBA 01/2016
1	IonsIBA 01/2016
1	LipopolysaccharidesIBA 01/2016
1	SilverIBA 01/2016
1	MetalsIBA 01/2016
1	lens epithelium-derived growth factorIBA 01/2016
1	LipidsIBA 09/2015
1	Glucose (Dextrose)FDA LinkGeneric 09/2015
1	LuteolinIBA 09/2015
1	oxysterol binding proteinIBA 07/2015
1	AllergensIBA 06/2015
1	Complementary DNA (cDNA)IBA 12/2013
1	DNA (Deoxyribonucleic Acid)IBA 12/2013
1	Amyloid (Amyloid Fibrils)IBA 02/2013

Therapy/Procedure

10	Therapeutics 10/2021 - 04/2004
4	Drug Therapy (Chemotherapy) 07/2009 - 03/2004